P0492 Development and Assessment of a Novel Ulcerative Colitis–Specific Quality of Life Questionnaire: A Prospective, Multi-Institutional Study

Field: Health Professions (Health Sciences)

Abstract Background Interest in the quality of life (QoL) of patients with inflammatory bowel disease (IBD) has recently increased. Althoughmeasurement tools have been devised for IBD in general, there is no specific tool for measuring the QoL of patients with ulcerativecolitis (UC). Therefore, we developed a QoL questionnaire specifically for patients with UC. Methods The Korean Ulcerative Colitis-Specific Questionnaire (K-UCSQ) was developed through item generation,raw-scale construction, focus group meetings, and multi-center field tests. Two hundred patients with UC were recruited for a fieldtest of the K-UCSQ, and subsequent responses to the Inflammatory Bowel Disease Questionnaire (IBDQ) were also obtained. Afterperforming factor analyses to ensure construct validity, the K-UCSQ was finalized as a four-domain, 28-item questionnaire. Subsequentanalyses evaluated the reliability of the K-UCSQ in terms of Cronbach’s alpha, concurrent validity in comparison with thepre-established IBDQ, and predictive validity of the area under the ROC curve (AUC) for clinically relevant QoL outcomes. Results A Cronbach’s alpha of 0.94 showed excellent reliability. Furthermore, correlation analyses demonstrated the concurrent validityof the K-UCSQ in comparison with the IBDQ. The K-UCSQ also showed high validity in predicting the perceived overall health(AUC of 0.812 vs. 0.797 using the IBDQ) and past 2-week QoL (AUC of 0.864 vs. 0.859 using the IBDQ). Conclusion The newly developed K-UCSQ is concise, bathroom problem-emphasizing, and UC-specific, suggesting that it couldbe a valid and reliable UC-specific instrument for QoL measurement. References 1.Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V,et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part1: initial diagnosis, monitoring of known IBD, detection of complications.J Crohns Colitis 2019;13:144-64. 2.Chang JT. Pathophysiology of inflammatory bowel diseases. N EnglJ Med 2020;383:2652-64. 3.Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, etal. British Society of Gastroenterology consensus guidelines onthe management of inflammatory bowel disease in adults. Gut2019;68(Suppl 3):S1-106. 4.Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM,et al. STRIDE-II: an update on the selecting therapeutic targets ininflammatory bowel disease (STRIDE) initiative of the internationalorganization for the study of IBD (IOIBD): determiningtherapeutic goals for treat-to-target strategies in IBD. Gastroenterology2021;160:1570-83. 5.Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-WalusA. Quality of life in inflammatory bowel disease: a systematic reviewand meta-analyses-part I. Inflamm Bowel Dis 2018;24:742-51. 6.Keller R, Mazurak N, Fantasia L, Fusco S, Malek NP, Wehkamp J, etal. Quality of life in inflammatory bowel diseases: it is not all aboutthe bowel. Intest Res 2021;19:45-52. 7.Knowles SR, Keefer L, Wilding H, Hewitt C, Graff LA, Mikocka-WalusA. Quality of life in inflammatory bowel disease: a systematic reviewand meta-analyses-part II. Inflamm Bowel Dis 2018;24:966-76. 8.Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, BushmakinAG, et al. The inflammatory bowel disease questionnaire in randomizedcontrolled trials of treatment for ulcerative colitis: systematicreview and meta-analysis. J Patient Cent Res Rev 2020;7:189-205. 9.Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, etal. A new measure of health status for clinical trials in inflammatorybowel disease. Gastroenterology 1989;96:804-10. 10.Stjernman H, Grännö C, Bodemar G, Järnerot G, Ockander L, TyskC, et al. Evaluation of the inflammatory bowel disease questionnairein Swedish patients with Crohn’s disease. Scand J Gastroenterol